

**John H. Stewart, IV, MD, MBA**, is the Physician Executive for Oncology Services for the University of Illinois Health System. He holds the rank of Professor with tenure in the University of Illinois, Chicago Department of Surgery and he is a Presidential Scholar for the University of Illinois. Dr. Stewart completed his general surgery residency at Vanderbilt University Medical Center and fellowships in surgical oncology, tumor immunology, and molecular oncology at the National Cancer Institute. The National Cancer Institute, Amgen, and the Robert Wood Johnson Foundation have funded his research efforts on oncolytic viruses.

**Mohammad Al Efishat, MD**, is a complex surgical oncology/hepatobiliary surgery fellow at Johns Hopkins Hospital. He is a graduate of the University of Jordan Medical School. Dr. Al Efishat completed his general surgery residency at Johns Hopkins along with a pancreas cancer basic and clinical research fellowship at Memorial Sloan Kettering Cancer Center.

**Fabian M. Johnston, MD, MHS**, is Associate Professor in the Department of Surgery at Johns Hopkins University where he also serves as Chief of the Section of Gastrointestinal Surgical Oncology, Director of the Peritoneal Surface Malignancy Program, and Program Director of the Complex General Surgical Oncology Program. Dr. Johnston completed residencies between the Louisiana State University School of Medicine and Washington University in St. Louis. He completed his complex general surgical oncology fellowship at the Johns Hopkins University. Dr. Johnston's research interests include utilization of highly innovative and novel strategies for the implementation of patient-centered models of care to improve utilization of palliative care amongst patients with advanced gastrointestinal malignancies.

**Edward Levine, MD**, is a nationally-recognized expert in surgical oncology. His practice is limited to treatment of patients with melanoma, sarcoma, breast and gastrointestinal cancer. He is a board-certified general surgeon and principal investigator of approximately 25 ongoing clinical research trials. He is an internationally renowned expert on the treatment of peritoneal malignancy. He serves as a leader in the Wake Forest Comprehensive Cancer Center and is the Chief of the surgical oncology service.

**Christopher W. Mangieri, MD**, is a complex surgical oncology fellow at Wake Forest University. He is a graduate of the Wake Forest University School of Medicine. Dr. Mangieri completed his general surgery residency at the Dwight D. Eisenhower Army Medical Center.

**Perry Shen, MD**, is Professor of Surgery at the Wake Forest University School of Medicine. His expertise is in the management of Gastrointestinal/hepato-pancreato-biliary cancers. For the past 3 years he has served as Leader of the Gastrointestinal Disease-Oriented Team at the Wake Forest Comprehensive Cancer Center. In this role he directed, supervised, and provided leadership for the development of clinical trials in Gastrointestinal/hepato-pancreato-biliary cancers. Dr. Shen also serves as Chair of the Protocol Review Committee for the Wake Forest Baptist Comprehensive Cancer Center and he oversees their Liver and Pancreas Surgery Program. Dr. Shen serves as the Associate Chair of Quality and Clinical Outcomes in the Wake Forest University Department of Surgery.

**Konstantinos Votanopoulos, MD, PhD**, is Professor of Surgery at Wake Forest University. He attended Aristotle University Medical School, Greece, completed residency in general surgery at Baylor College of Medicine, and surgical oncology fellowship at Roswell Park Cancer Institute. Dr. Votanopoulos has also received a PhD degree in tumor biology from the University of Athens, Greece. He maintains a clinical focus on peritoneal surface malignancies, sarcomas, and melanoma. His research focuses in peritoneal surface malignancies as well as organoid technology applications in personalized cancer care and adaptive immunity.

**Omeed Moaven, MD**, is Assistant Professor of Surgery at the Mayo Clinic in Jacksonville, Florida. He is a graduate of Mashhad University of Medical Sciences and the University of

Alabama, Birmingham general surgery residency program. Dr. Moaven completed fellowships in Surgical Oncology at Wake Forest University and oncology research at the Massachusetts General Hospital.

**Jason M. Foster, MD**, is Associate Professor of Surgery at the Fred and Pamela Buffet Cancer at the University of Nebraska in the Division of Surgical Oncology, Department of Surgery. He received his medical degree from Temple University in Philadelphia Pennsylvania. He completed general surgery residency at the Case Western Reserve/University Hospital in Cleveland, Ohio, followed by surgical oncology fellowship training at the Roswell Park Cancer Institute Buffalo. He joined the faculty at University of Nebraska to develop and lead regional cancer therapies and complex gastrointestinal malignancies programs. His clinical areas includes peritoneal disease, Gastrointestinal malignancies, sarcoma, and melanoma and his research focuses on peritoneal metastasis both clinical outcomes, clinical trials, and collaborative translation studies identifying/exploring pathways involved in peritoneal metastasis in appendix, colorectal, and ovarian cancers, and mesothelioma.

**Taylor M. Carter, MD**, is a resident in general surgery at the University of North Carolina. He is a graduate of the BA/MD program at the University of Missouri, Kansas City.

**Ugwuji N. Maduekwe, MD, MMSc**, is Assistant Professor of Surgery in the Division of Surgical Oncology and Endocrine Surgery at the University of North Carolina at Chapel Hill. She graduated with an MD from the Harvard-MIT Health, Sciences and Technology Pathway at Harvard Medical School and completed a residency in general surgery at Massachusetts General Hospital, and complex general surgical oncology fellowship at the University of Pittsburgh Medical Center. She maintains a clinical interest in pancreaticobiliary and peritoneal surface malignancies with research focused on disparities in access to the multidisciplinary care of gastrointestinal malignancies.

**Austin Eckhoff, MD**, is a resident in general surgery at Duke University. She graduated from Emory School of Medicine and is interested in hepatobiliary surgery. Her research interests are in tumor immunology pertaining to intraductal papillary mucinous neoplasm (IPMN) and better predicting which IPMN will transform into pancreatic cancer.

**Dan G. Blazer, MD**, is Associate Professor of Surgery in the Division of Surgical Oncology, Department of Surgery, Duke University Medical Center. He graduated from the Duke University School of Medicine and, received his training in general surgery at the University of Michigan. During that time, he completed a 2-year research fellowship in surgical oncology at the Surgery Branch, National Cancer Institute, National Institutes of Health, in Bethesda, MD. He went on to complete a fellowship in surgical oncology at the MD Anderson Cancer Center. Since that time, he has been on the faculty at Duke University. He is the Program Director for the complex general surgical oncology fellowship. His clinical practice focuses primarily on the surgical management of gastrointestinal malignancies, including gastric cancer, soft tissue sarcoma, and peritoneal surface malignancies.

**Deemantha Fernando, MD**, received his medical degree from Kursk State Medical University, Russia. He is currently pursuing clinical research at the Medical College of Wisconsin in the Department of Surgery, Division of Surgical Oncology.

**Harveshp Mogal, MD, MS**, is Assistant Professor of Surgery/ Surgical Oncology at the Medical College of Wisconsin in Milwaukee, WI. He received his medical degree and subsequently completed a residency in general surgery from the University of Bombay. He then completed a residency in general surgery at Saint Louis University and a fellowship in complex general surgical oncology at the Wake Forest University School of Medicine. He then obtained a Masters in Clinical and Translational Science from the Medical College of Wisconsin in

Milwaukee, WI. His clinical and research interests focus on the management of patients with GI malignancies, peritoneal surface malignancies, melanoma and sarcoma.

**Timothy B Lautz, MD**, is an academic pediatric general surgeon who specializes in the care of children with cancer. He holds the position of Assistant Professor of Surgery at the Northwestern University Feinberg School of Medicine. He has an expertise in utilizing large national databases to analyze clinical outcomes in children with common surgical conditions. His clinical research is focused on outcomes in children with cancer.

**Andrea Hayes Jordan, MD**, is professor of Pediatric Surgery and Surgical Oncology at the University of North Carolina Children's Hospital. She is the Surgeon-in-Chief of the UNC Children's Hospital and the Division Chief of pediatric surgery at UNC. Hayes-Jordan has a basic science laboratory which focuses on rare sarcomas. She specializes in refractory and resistant tumors in children and specifically soft tissue sarcomas and children. She has impacted the field of sarcoma and sarcomatosis by amassing the largest number of desmoplastic small round cell tumor DSRCT patients at any single hospital and by any one surgeon. DSRCT is a rare disease for which she has improved the survival rate from 30% to 60% based on complete removal of 100s of intra-abdominal tumor implants and HIPEC.

**Maria Jose Calderon, PhD**, is a Postdoctoral Research Associate at the University of Illinois at Chicago Cancer Center. In this role, she is involved in the development of cancer immunotherapies for peritoneal malignancies, focused on oncolytic viruses. Dr. Godoy's previous experience includes studies in breast cancer immunotherapy based on an autologous vaccine combined with BCG and anti-PD-1. Her published work demonstrated the effectiveness of this immunotherapy at a preclinical level. Dr. Godoy obtained her Ph.D. degree at Universidad Simon Bolivar in Venezuela, focused on the molecular study of acute myeloid leukemias.